Homology Medicines has joined the growing list of biotechs hitting a wall in 2023, with the gene therapy-focused company blaming the “current financing environment” for the move to lay off 87% of ...
Homology Medicines is adding an immunosuppressive regimen to a phase 1/2 trial for its phenylketonuria gene therapy, hoping to quell FDA concerns that triggered a clinical hold in February. The agency ...
BEDFORD, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the successful closing of the deal with Oxford Biomedica plc ...
BEDFORD, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that it has completed a review of its business, and the Board of ...
This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor ...
In recent years, CRISPR-Cas9 genome editing has enjoyed spectacular success because it combines flexibility and usability. The Cas9 nuclease need only be loaded with a guide RNA to direct it to almost ...
Gene editing company Homology Medicines (NASDAQ:FIXX) added ~23% pre-market Friday after announcing that the company intends to evaluate strategic alternatives, including potential partnerships, a ...
Molecular biology has transitioned to a new era where precise genetic manipulation plays a critical role in research, medicine, and biotechnology. Among the vital tools in this field are cloning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results